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Between Community and Hospital: Healthcare-Associated
Gram-Negative Bacteremia among Hospitalized Patients
Jonas Marschall, MD; Victoria J. Fraser, MD; Joshua Doherty, BS; David K. Warren, MD, MPH
objective. Healthcare-associated, community-acquired bacteremia is a subcategory of community-acquired bacteremia distinguished
by recent exposure of the patient to the healthcare system before hospital admission. Our objective was to apply this category to a prospective
cohort of hospitalized patients with gram-negative bacteremia to determine differences in the epidemiological characteristics, treatment,
and outcome of community-acquired bacteremia; healthcare-associated, community-acquired bacteremia; and hospital-acquired bacteremia.
design. A 6-month prospective cohort study.
setting. A 1,250-bed tertiary care hospital.
patients. Adults hospitalized with gram-negative bacteremia.
results. Among 250 patients, 160 (64.0%) had bacteremia within 48 hours after admission; 132 (82.5%) of these were considered to
have healthcare-associated, community-acquired bacteremia, according to previously published criteria. For patients with healthcare-as-
sociated, community-acquired bacteremia, compared with patients with community-acquired bacteremia, malignancies (59 [44.7%] of 132
patients vs 3 [10.7%] of 28 patients; ), open wounds at admission (42 [31.8%] vs 3 [10.7%]; ), and intravascular catheter–Pp .001 Pp .02
related infections (26 [19.7%] vs 0; ) were more frequent and Escherichia coli as a causative agent was less frequent (16 [57.1%]Pp .009
vs 33 [25.0%]; ). There was no difference between these 2 groups in inadequate empirical antibiotic treatment (36 [27.3%] vs 6Pp .001
[21.4%]; ) and hospital mortality (18 [13.6%] vs 2 [[7.1%]; ). Compared with 90 patients with hospital-acquired bacteremia,Pp .5 Pp .5
patients with healthcare-associated, community-acquired bacteremia had a higher Charlson score (odds ratio [OR], 1.31 [95% confidence
interval (CI), 1.14–1.49]) but were less likely to have lymphoma (OR, 0.07 [95% CI, 0.01–0.51]), neutropenia (OR, 0.21 [95% CI, 0.07–
0.61]), a removable foreign body (OR, 0.08 [95% CI, 0.03–0.20]), or Klebsiella pneumoniae infection (OR, 0.26 [95% CI, 0.11–0.62]).
conclusions. Many cases of gram-negative bacteremia that occurred in hospitalized patients were healthcare associated. The patients
differed in some aspects from patients with community-acquired bacteremia and from those with hospital-acquired bacteremia, but not
in mortality.
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The distinction between community- and hospital-acquired
infections among hospitalized patients is becoming increas-
ingly blurred. Shorter hospital stays, increased outpatient
delivery of care, and a rising number of immunocompro-
mised patients in the community account for some of
these changes.1,2 In many cases, the definition of community
acquisition does not reflect the increasing number of patients
who were exposed to the healthcare system before being ad-
mitted to the hospital. Although the difference between com-
munity- and hospital-acquired bacteremia has been studied
previously,3 the Centers for Disease Control and Prevention
definitions of nosocomial infections do not account for
healthcare-associated, community-acquired bacteremia (re-
ferred to hereafter as healthcare-associated bacteremia),4 and
they maintain the dichotomous concept of community versus
hospital acquisition. This has led to calls for a revised clas-
sification of bloodstream infections.5
In 2002, Friedman and colleagues proposed a new classi-
fication of community-acquired bloodstream infections and
established the use of the term healthcare-associated blood-
stream infection. Applying a set of 4 criteria, they found many
similarities between patients with healthcare-associated in-
fection and those with hospital-acquired infection, in terms
of comorbid conditions, sources of infection, presence of mi-
crobial pathogens, and susceptibility patterns.6 They argued
that empirical antibiotic treatment should be tailored ac-
cording to this classification. Since then, few published articles
have scrutinized the new classification.7-10 Shorr et al used a
large US database to test the new classification retrospectively
in bacterial and fungal bloodstream infections,8 whereas Les-
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ens et al and Liao et al restricted their studies to healthcare-
associated Staphylococcus aureus bacteremia.7,10 More recently,
other terms have been proposed to reflect the circumstances
of the acquisition of infection, such as community-acquired
healthcare-associated infection11 or community-onset health-
care-associated infection.12
Our objective was to apply the definition by Friedman and
colleagues of “healthcare association” to a prospective cohort
of hospitalized patients with gram-negative bacteremia, to
determine differences in the epidemiological characteristics,
treatment, and outcome of community-acquired bactere-




Barnes-Jewish Hospital, a 1,250-bed teaching hospital, is the
largest hospital in Missouri and has a referral base that in-
cludes the St Louis metropolitan area, eastern Missouri, and
western Illinois. It houses all medical specialties, including a
bone marrow transplantation unit. It is affiliated with Wash-
ington University School of Medicine.
Study Design
We performed a 6-month, prospective cohort study of pa-
tients with gram-negative bacteremia from August 1, 2006,
through January 31, 2007. We received daily electronic no-
tification of all patients with blood cultures positive for any
organism on a list of specified gram-negative bacilli. The
automated query was run on a daily basis through the Barnes-
Jewish Hospital Medical Informatics database, and results
were sent daily to 1 of the investigators (J.M.).
Inclusion and Exclusion Criteria
All adult patients admitted to acute care wards who presented
with or developed gram-negative bacteremia were included.
Patients were considered to have gram-negative bacteremia
if they had least 1 positive culture result; if patients had more
than 1 bacteremia episode, only the first episode was used
for this analysis. Polymicrobial infections were also included.
Patients who were bacteremic as outpatients (in clinics or in
the emergency department) and who were sent home before
a blood culture returned positive results were excluded be-
cause we could not determine with certainty the treatment
that these patients received.
Data Collection
Paper and electronic medical records were reviewed for de-
mographic information, medical history, home medications,
vital signs, microbiological information, diagnostic and ther-
apeutic procedures, and antimicrobial medication. All of these
sources were reviewed daily during the hospital stay. Special
attention was given to 2 areas of information: To determine
the adequacy of antibiotic therapy, microbiological infor-
mation was entered sequentially as time blood sample was
obtained, time of notification of positive culture and Gram
stain results, time of identification of microorganism, and
time of notification of antibiotic susceptibilities. Start and
stop dates and times for the use of each antibiotic were en-
tered sequentially.
Charlson comorbidity13 and McCabe severity of illness14
scores at admission were determined. The key clinical out-
comes measured included the development of sepsis and hy-
potension, the subsequent transfer to the intensive care unit,
length of hospital stay after detection of positive blood cul-
ture results, and in-hospital mortality.
Definitions
Sepsis and sepsis-induced hypotension were defined accord-
ing to established criteria.15 Inadequate empirical antibiotic
treatment was defined as either no antibiotic administered or
no antibiotic administered to which all bacteria were suscep-
tible within 24 hours after blood sample was obtained.16
Patients received a diagnosis of community-acquired,
gram-negative bacteremia if their first positive blood culture
results were obtained from blood samples drawn within 48
hours after hospital admission.3 Cases of community-ac-
quired bacteremia were further classified as being healthcare
associated if 1 or more of the following criteria were present:
outpatient treatment, hemodialysis, or intravenous chemo-
therapy during the past 30 days; hospitalization for at least
2 days during the past 90 days; home intravenous therapy or
wound care during the past 30 days; or residence in a long-
term care facility.6
Data Analysis and Statistical Methods
Data entry was performed with Microsoft Access and Excel
(Microsoft). Data were analyzed with SPSS, version 14 (SPSS).
Univariate comparisons among categorical variables were
performed by use of the x2 test or the Fisher exact test as
appropriate. Comparisons among continuous independent
variables were performed by use of the Student t test or the
Mann-Whitney U test as appropriate. Variables found to have
a P value of less than .1 on univariate testing were considered
for entry into a forward, stepwise multivariate logistic re-
gression model. Multivariate analysis was applied to the com-
parison of healthcare-associated bacteremia and hospital-
acquired bacteremia, but because of the small numbers, a
multivariate analysis could not be applied to the comparison
of healthcare-associated bacteremia and community-acquired
bacteremia (ie, bacteremia in patients without any known
healthcare exposure). A 2-sided P value of less than .05 was
considered to indicate a statistically significant difference. The
study was approved by the Washington University Human
Research Protection Office.
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figure 1. Differentiation of hospitalized patients with gram-
negative bacteremia, according to method of acquisition.
table 1. Frequency of the 4 Criteria That Define Health-





Outpatient treatment, hemodialysis, intra-
venous chemotherapy in the past 30 days 102 (77.3)
Hospitalization for 11 day in the past 90 days 95 (72.0)
Intravenous therapy or wound care at home
in the past 30 days 32 (24.2)
Residence in long-term care facility 26 (19.7)
a More than 1 criterion can be present in a single patient; therefore,
the total exceeds 132.
results
Frequency of Healthcare-Associated Infection
among Hospitalized Patients
with Gram-Negative Bacteremia
We included 250 hospitalized patients with gram-nega-
tive bacteremia in our study (Figure). One hundred sixty
(64.0%) of them had community-acquired bacteremia, and
90 (36.0%) had hospital-acquired bacteremia. Overall, 207
patients (82.8%) in the cohort had prior exposure to the
healthcare system.
Among the subset of 160 patients with bacteremia within
48 hours after admission, 132 (82.5%) had healthcare-asso-
ciated bacteremia, and 28 (17.5%) had community-acquired
bacteremia. Of the 90 patients with hospital-acquired bacter-
emia, 75 (83.3%) had prior exposure to the healthcare system.
For the 132 patients with healthcare-associated bacteremia,
we examined the 4 criteria that define healthcare association
(Table 1). The criterion most frequently present was outpa-
tient treatment, hemodialysis, or intravenous chemotherapy
(ie, 102 [77.3%] of 132 patients). Forty patients (30.3%) re-
ceived a diagnosis of healthcare-associated infection on the
basis of 1 criterion, 67 patients (50.8%) on the basis of 2
criteria, 19 patients (14.4%) on the basis of 3 criteria, and 6
patients (4.5%) on the basis of all 4 criteria.
Comparison of Healthcare-Associated Bacteremia
and Community-Acquired Bacteremia
Compared with patients with community-acquired bacter-
emia (Table 2), patients with healthcare-associated bacteremia
were older (mean  standard deviation, 57.9  15.8 years
vs 54.5 20.4 years; ), had a higher Charlson scorePp .046
(median [range], 4 [0–16] vs 1 [0–15]; ), and werePp .005
more severely ill (mean McCabe score, 1.54 vs 1.25; Pp
). Malignant tumors were more frequent among the 132.02
patients with healthcare-associated bacteremia than they were
among the 28 patients with community-acquired bacteremia
(59 [44.7%] vs 3 [10.7%]; ), as were skin woundsPp .001
at admission (42 [31.8%] vs 3 [10.7%]; ) or the pres-Pp .02
ence of a removable foreign body at the time of infection (69
[52.3%] vs 8 [28.6%]; ). Compared with patients withPp .02
community-acquired bacteremia, for patients with health-
care-associated bacteremia, the urinary tract was less fre-
quently the source of infection (38 [28.8%] vs 16 [57.1%];
), intravascular catheters were a more commonPp .004
source of infection (26 [19.7%] vs 0; ), and Esch-Pp .009
erichia coli (monomicrobial bacteremia) was less frequently
involved (33 [25.0%] vs 16 [57.1%]; ).Pp .001
There was no significant difference in the administration of
inadequate empirical antibiotic treatment (36 [27.3%] health-
care-associated cases vs 6 [21.4%] community-acquired cases;
), in transfer to the intensive care unit (46 [34.8%] vsPp .5
5 [17.9%]; ), in length of hospital stay after the positivePp .08
blood culture sample was obtained (median, 5.5 [range, 0–
89.3] vs 4.2 [0–34.6] days; ), or in in-hospital mortalityPp .09
(18 [13.6%] vs 2 [7.1%]; ) (Table 2).Pp .5
Comparison of Healthcare-Associated Bacteremia
and Hospital-Acquired Bacteremia
Compared with patients with hospital-acquired bacteremia,
patients with healthcare-associated bacteremia (Table 3) had
a lower severity of illness (mean McCabe score, 1.54 vs 1.76;
). Lymphoma was less frequent among the 132 pa-Pp .04
tients with healthcare-associated bacteremia than it was
among the 90 patients with hospital-acquired bacteremia (2
[1.5%] vs 13 [14.4%]; ), as was leukemia (8 [6.1%]P ! .001
vs 19 [21.1%]; ), neutropenia prior to the bacteremiaPp .001
(9 [6.8%] vs 27 [30.0%]; ), mucositis (6 [4.5%] vsP ! .001
15 [16.7%]; ), and the presence of a removable for-Pp .002
eign body (69 [52.3%] vs 81 [90.0%]; ). Conversely,P ! .001
metastatic solid tumors were more frequent among patients
with healthcare-associated bacteremia than they were among
patients with hospital-acquired bacteremia (27 [20.5%] vs 4
[4.4%]; ), as was dementia (14 [10.6%] vs 1 [1.1%];Pp .001
).Pp .006
Compared with patients with hospital-acquired bacteremia,
for patients with healthcare-associated bacteremia, the source
of infection was more often the urinary tract (38 [28.8%] vs
13 [14.4%]; ) and remained less frequently unknownPp .01
(27 [20.5%] vs 32 [35.6%]; ). E. coli was more com-Pp .01











(n p 28) P
Age, years, mean  SD 57.9  15.8 54.5  20.4 .046
Male sex 69 (52.3) 9 (32.1) .05
Body mass index, median (range) 26.4 (13.3–66.4) 28.9 (16.8–70.4) .2
Charlson score
Mean 4.8 3.2 .005
Median (range) 4 (0–16) 1 (0–15)
McCabe score
Mean 1.54 1.25 .02
Median (range) 1 (1–3) 1 (1–3)
Comorbidities
Congestive heart failure 19 (14.4) 2 (7.1) .5
Chronic pulmonary disease 25 (18.9) 3 (10.7) .4
Malignant tumor 59 (44.7) 3 (10.7) .001
Lymphoma 2 (1.5) 0 1.99
Leukemia 8 (6.1) 0 .4
Metastatic solid tumor 27 (20.5) 3 (10.7) .2
Diabetes mellitus 49 (37.1) 13 (46.4) .4
Cerebrovascular disease 19 (14.4) 2 (7.1) .5
Dementia 14 (10.6) 1 (3.6) .5
Hemiplegia 8 (6.1) 0 .4
Moderate or severe liver disease 8 (6.1) 1 (3.6) 1.99
Neutropenia 9 (6.8) 0 .4
Renal insufficiencya 42 (31.8) 7 (25.0) .5
Hyperglycemiab 22 (16.7) 7 (25.0) .3
Mucositis 6 (4.5) 0 .6
Skin wound at admission 42 (31.8) 3 (10.7) .02
Skin incision at admission 16 (12.1) 0 .08
Removable foreign body presentc 69 (52.3) 8 (28.6) .02
Source of infection
Urinary tract 38 (28.8) 16 (57.1) .004
Intravascular catheter 26 (19.7) 0 .009
Gastrointestinal or hepatobiliary system 22 (16.7) 4 (14.3) 1.99
Unknown 27 (20.5) 6 (21.4) .9
Causative microorganism
Escherichia coli 33 (25.0) 16 (57.1) .001
Klebsiella pneumoniae 20 (15.2) 2 (7.1) .3
Pseudomonas aeruginosa 9 (6.8) 0 .4
Multidrug-resistant organismd 7 (5.3) 0 .6
Outcome measures
Inadequate empirical antibiotic
treatment 36 (27.3) 6 (21.4) .5
Sepsis 118 (89.4) 25 (89.3) 1.99
Sepsis-induced hypotension 62 (47.0) 8 (28.6) .8
Transfer to intensive care unit 46 (34.8) 5 (17.9) .08
Postbacteremia length of hospital stay,
median (range), days 5.5 (0–89.3) 4.2 (0–34.6) .09
In-hospital death 18 (13.6) 2 (7.1) .5
note. Data are no. (%) of patients unless otherwise indicated. SD, standard deviation.
a Creatinine level, 11.5 mg/dL.
b Glucose level, 1200 mg/dL.
c At the time when the blood sample was obtained for the first culture that returned positive results.
d Resistance to cephalosporins, aminoglycosides, and fluoroquinolones.17
table 3. Comparison of 222 Hospitalized Patients with Gram-Negative Bacteremia That Is Associated










(n p 90) P OR (95% CI)
Age, years, mean  SD 57.9  15.8 54.9  15.1 .2
Male sex 69 (52.3) 48 (53.3) .9
Body mass index, median (range) 26.4 (13.3–66.4) 26.2 (14.6–59.9) 1.99
Charlson score 1.31 (1.14–1.49)
Mean 4.8 3.7 .05
Median (range) 4 (0–16) 4 (0–12)
McCabe score
Mean 1.54 1.76 .04
Median (range) 1 (1–3) 2 (1–3)
Comorbidities
Congestive heart failure 19 (14.4) 9 (10.0) .3
Chronic pulmonary disease 25 (18.9) 16 (17.8) .8
Malignant tumor 59 (44.7) 50 (55.6) .1
Lymphoma 2 (1.5) 13 (14.4) !.001 0.07 (0.01–0.51)
Leukemia 8 (6.1) 19 (21.1) .001
Metastatic solid tumor 27 (20.5) 4 (4.4) .001
Diabetes mellitus 49 (37.1) 25 (27.8) .1
Cerebrovascular disease 19 (14.4) 7 (7.8) .1
Dementia 14 (10.6) 1 (1.1) .006
Hemiplegia 8 (6.1) 7 (7.8) .6
Moderate or severe liver disease 8 (6.1) 2 (2.2) .2
Neutropenia 9 (6.8) 27 (30.0) !.001 0.21 (0.07–0.61)
Renal insufficiencya 42 (31.8) 19 (21.1) .08
Hyperglycemiab 22 (16.7) 12 (13.3) .5
Mucositis 6 (4.5) 15 (16.7) .002
Skin wound at admission 42 (31.8) 29 (32.2) .9
Skin incision at admission 16 (12.1) 7 (7.8) .3
Removable foreign body presentc 69 (52.3) 81 (90.0) !.001 0.08 (0.03–0.20)
Sources of infection
Urinary tract 38 (28.8) 13 (14.4) .01
Intravascular catheter 26 (19.7) 14 (15.6) .4
Gastrointestinal or hepatobiliary system 22 (16.7) 15 (16.7) 1.99
Unknown 27 (20.5) 32 (35.6) .01
Causative microorganism
Escherichia coli 33 (25.0) 10 (11.1) .01
Klebsiella pneumoniae 20 (15.2) 23 (25.6) .05 0.26 (0.11–0.62)
Pseudomonas aeruginosa 9 (6.8) 10 (11.1) .3
Multidrug-resistant organismd 7 (5.3) 5 (5.6) 1.99
Outcome measures
Inadequate empirical antibiotic treatment 36 (27.3) 37 (41.1) .03
Sepsis 118 (89.4) 88 (97.8) .02
Sepsis-induced hypotension 62 (47.0) 35 (38.9) .2
Transfer to intensive care unit 46 (34.8) 19 (21.1) .03
Postbacteremia length of hospital stay,
median (range), days 5.5 (0–89.3) 8.0 (0–105.6) .002
In-hospital death 18 (13.6) 15 (16.7) .5
note. Data are no. (%) unless otherwise indicated. CI, confidence interval; OR, odds ratio; SD, standard deviation.
Variables considered for entry in a forward stepwise multivariate logistic regression model included McCabe severity of
illness score at admission, Charlson comorbidity score at admission, leukemia, lymphoma, any malignant disease, met-
astatic solid tumor, neutropenia prior to bacteremia, diabetes mellitus, cerebrovascular disease, source in urinary tract,
unknown source of bacteremia, monomicrobial infection with E. coli, monomicrobial infection with K. pneumoniae,
serum creatinine level 11.5 mg/dL at admission, mucositis, and removable foreign body present. The 2 log likelihood
value for the final model was 213.745, and the Hosmer-Lemeshow goodness-of-fit x2 test value was 12.193 ( ).Pp .143
a Creatinine level, 11.5 mg/dL.
b Glucose level, 1200 mg/dL.
c At the time when the blood sample was obtained for the first culture that returned positive results.
d Resistance to cephalosporins, aminoglycosides, and fluoroquinolones.17
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monly the causative pathogen in healthcare-associated infec-
tions (33 [25.0%] vs 10 [11.1%]; ).Pp .01
The administration of empirical antibiotic treatment was
less often inadequate in cases of healthcare-associated bac-
teremia than it was in cases of hospital-acquired bacteremia
(36 [27.3%] vs 37 [41.1%]; ). Sepsis was less frequentPp .03
in cases of healthcare-associated bacteremia than it was in
cases of hospital-acquired bacteremia (118 [89.4%] vs 88
[97.8%]; ), and the length of hospital stay after de-Pp .02
tection of bacteremia was shorter in the former group (me-
dian [range], 5.5 [0–89.3] vs 8.0 [0–105.6] days; ).Pp .002
Transfer to the intensive care unit more frequently occurred
among patients with healthcare-associated bacteremia than it
did among patients with hospital-acquired bacteremia (46
[34.8%] vs 19 [21.1%]; ). However, there was noPp .03
significant difference in in-hospital mortality (18 patients
[13.6%] with healthcare-associated bacteremia vs 15 patients
[16.7%] with hospital-acquired bacteremia; ).Pp .5
In multivariate analysis (Table 3), a higher Charlson score
(odds ratio [OR], 1.31 [95% confidence interval {CI}, 1.14–
1.49]; ) was associated with healthcare-associatedP ! .001
bacteremia. Patients with healthcare-associated bacteremia
were less likely to have lymphoma (OR, 0.07 [95% CI, 0.01–
0.51]; ), neutropenia (OR, 0.21 [95% CI, 0.07–0.61];Pp .009
), a removable foreign body (OR, 0.08 [95% CI,Pp .004
0.03–0.20]; ), or Klebsiella pneumoniae infection (OR,P ! .001
0.26 [95% CI, 0.11–0.62]; ) than were patients withPp .003
hospital-acquired bacteremia.
discussion
Only a few studies have examined the utility of the new
classification of community-acquired bacteremia proposed by
Friedman et al.6 Lesens et al and Liao et al performed pro-
spective studies on S. aureus infection,7,10 and Shorr et al used
a large preexisting database to collect information retrospec-
tively on various bloodstream infections.8
In our study, the majority of cases of bacteremia (82.5%)
that would conventionally be classified as community ac-
quired were in fact healthcare associated. This is higher than
the 56.5%–59.5% reported elsewhere.6,8 In the subgroup of
gram-negative bacteria described by Shorr et al, the per-
centage of bloodstream infections that were healthcare-as-
sociated infections was lower than that seen in our study
(56.7%). Similarly, Friedman’s group reported that 50.9% of
their 159 cases of gram-negative bacteremia were healthcare
associated.18 There are several possible explanations for the
increased proportion of patients with healthcare-associated
infections in our study. As a result of the prospective design
of our study, we may have improved the ascertainment of
recent exposure to the healthcare system. Although previous
studies also included tertiary care centers, factors unique to
our setting may have played an additional role (eg, a large
population of bone marrow transplant recipients and cancer
patients). This is supported by the observation that the ma-
jority (63.8%) of patients with healthcare-associated bacter-
emia in our study had outpatient treatment, hemodialysis, or
intravenous chemotherapy during the prior 30 days, com-
pared with only 78 of 186 patients (42%) in an earlier study.6
Urinary tract infections were the most common source of
community-acquired bacteremia, and they were a less com-
mon source in healthcare-associated and hospital-acquired
bacteremia. This has been reported elsewhere.6 E. coli, prob-
ably the most important pathogen in gram-negative com-
munity-acquired infections,8 followed that trend closely in
our population, and the pattern was similar to that in the
population of the Shorr et al study. Unlike the work of Shorr
et al, however, which included only patients with bacteremia
detected during the first 5 days of hospitalization—which
might have distorted the epidemiological characteristics of
nosocomial pathogens—our data account for the entire hos-
pital stay.
Patients with community-acquired bacteremia were less
likely to have malignancies or to have intravascular catheters
as a source of bacteremia than those with healthcare-associ-
ated bacteremia. Patients with hospital-acquired bacteremia
were more likely to have neutropenia or lymphoma than were
patients with healthcare-associated bacteremia. In summary,
several characteristics distinguish community-acquired bac-
teremia from healthcare-associated bacteremia and hospital-
acquired bacteremia. Our findings therefore justify the re-
classification by Friedman et al.6,10
Whether the adequacy of empirical antibiotic treatment is
an important prognostic factor in bloodstream infections is
unclear: some studies show worse outcomes,19,20 whereas oth-
ers fail to demonstrate a detrimental effect of inadequate
treatment.16,18 We did not find a difference in the adminis-
tration of inadequate treatment between healthcare-associ-
ated bacteremia and community-acquired bacteremia. Pa-
tients with hospital-acquired infections, however, were more
likely to receive inadequate treatment, which has been re-
ported elsewhere.16,19
We did not find a difference in mortality rates among the
3 groups, however. This is different from the results of pre-
vious studies, which reported an increased risk of inadequate
treatment for healthcare-associated bacteremia18 and signifi-
cantly higher mortality from healthcare-associated bacteremia
than from community-acquired bacteremia.6,8 Shorr and col-
leagues hypothesized that poor outcome in healthcare-asso-
ciated infections might be largely due to the S. aureus subset,
but they did not collect data on adequacy of treatment. Other
authors could not detect differences in mortality attributable
to S. aureus bacteremia among the 3 groups of patients.7,10
Because Shorr et al did not display separate mortality rates
for infections caused by gram-negative organisms, there are
no data available for comparison of our findings.
There are a few limitations to our study. First, our study
was restricted in terms of the group of microorganisms and
in terms of patient selection, by excluding patients not suf-
ficiently ill to be admitted to the hospital. In addition, the
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study was performed in a tertiary care center with a large
oncology department and distinct empirical prescribing pat-
terns, which might reduce the generalizability of our findings.
Our study demonstrates that there are differences, as well
as overlapping areas, in the epidemiological characteristics of
community-acquired bacteremia, healthcare-associated bac-
teremia, and hospital-acquired bacteremia. The category of
healthcare-associated bacteremia seems to represent a tran-
sitional state between community- and hospital-acquired bac-
teremia. The original intention of distinguishing healthcare-
associated bacteremia from community-acquired bacteremia
was to improve empirical treatment of patients at hospital
admission. While our study noted differences in the micro-
biological characteristics of gram-negative pathogens between
community-acquired bacteremia and healthcare-associated
bacteremia, there was no difference in adequacy of empirical
treatment or subsequent outcomes between these 2 types of
bacteremia. Although this classification is useful to elicit ep-
idemiological nuances, it remains to be seen whether larger
prospective studies will show that the reclassification has an
effect on clinical outcomes.
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